PE20080124A1 - AEROSOL FORMULATIONS CONTAINING S-FLUOROMETHYL ESTER OF 6ALPHA, 9ALPHA-DIFLUORO-17ALPHA [(2-FURANYLCARBONYL) OXY] -11BETA-HYDROXY-16ALPHA-METHYL-3-OXO-ANDROSTE, 1,4-DIENO-CARBONYL - Google Patents
AEROSOL FORMULATIONS CONTAINING S-FLUOROMETHYL ESTER OF 6ALPHA, 9ALPHA-DIFLUORO-17ALPHA [(2-FURANYLCARBONYL) OXY] -11BETA-HYDROXY-16ALPHA-METHYL-3-OXO-ANDROSTE, 1,4-DIENO-CARBONYLInfo
- Publication number
- PE20080124A1 PE20080124A1 PE2007000310A PE2007000310A PE20080124A1 PE 20080124 A1 PE20080124 A1 PE 20080124A1 PE 2007000310 A PE2007000310 A PE 2007000310A PE 2007000310 A PE2007000310 A PE 2007000310A PE 20080124 A1 PE20080124 A1 PE 20080124A1
- Authority
- PE
- Peru
- Prior art keywords
- androste
- 9alpha
- 6alpha
- dieno
- 17alpha
- Prior art date
Links
- 239000000203 mixture Substances 0.000 title abstract 4
- -1 2-FURANYLCARBONYL Chemical class 0.000 title abstract 2
- 239000000443 aerosol Substances 0.000 title abstract 2
- 239000008194 pharmaceutical composition Substances 0.000 abstract 2
- XWTYSIMOBUGWOL-UHFFFAOYSA-N (+-)-Terbutaline Chemical compound CC(C)(C)NCC(O)C1=CC(O)=CC(O)=C1 XWTYSIMOBUGWOL-UHFFFAOYSA-N 0.000 abstract 1
- GIIZNNXWQWCKIB-VWLOTQADSA-N (R)-salmeterol Chemical compound C1=C(O)C(CO)=CC([C@@H](O)CNCCCCCCOCCCCC=2C=CC=CC=2)=C1 GIIZNNXWQWCKIB-VWLOTQADSA-N 0.000 abstract 1
- YFMFNYKEUDLDTL-UHFFFAOYSA-N 1,1,1,2,3,3,3-heptafluoropropane Chemical compound FC(F)(F)C(F)C(F)(F)F YFMFNYKEUDLDTL-UHFFFAOYSA-N 0.000 abstract 1
- 208000006545 Chronic Obstructive Pulmonary Disease Diseases 0.000 abstract 1
- GIIZNNXWQWCKIB-UHFFFAOYSA-N Serevent Chemical compound C1=C(O)C(CO)=CC(C(O)CNCCCCCCOCCCCC=2C=CC=CC=2)=C1 GIIZNNXWQWCKIB-UHFFFAOYSA-N 0.000 abstract 1
- 239000013543 active substance Substances 0.000 abstract 1
- NDAUXUAQIAJITI-UHFFFAOYSA-N albuterol Chemical compound CC(C)(C)NCC(O)C1=CC=C(O)C(CO)=C1 NDAUXUAQIAJITI-UHFFFAOYSA-N 0.000 abstract 1
- 208000006673 asthma Diseases 0.000 abstract 1
- 229920000249 biocompatible polymer Polymers 0.000 abstract 1
- 150000001875 compounds Chemical class 0.000 abstract 1
- 238000009472 formulation Methods 0.000 abstract 1
- 238000000034 method Methods 0.000 abstract 1
- 229920000642 polymer Polymers 0.000 abstract 1
- 229960002052 salbutamol Drugs 0.000 abstract 1
- 229960004017 salmeterol Drugs 0.000 abstract 1
- 229960000195 terbutaline Drugs 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/007—Pulmonary tract; Aromatherapy
- A61K9/0073—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy
- A61K9/008—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy comprising drug dissolved or suspended in liquid propellant for inhalation via a pressurized metered dose inhaler [MDI]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
- A61K31/58—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids containing heterocyclic rings, e.g. danazol, stanozolol, pancuronium or digitogenin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L2/00—Methods or apparatus for disinfecting or sterilising materials or objects other than foodstuffs or contact lenses; Accessories therefor
- A61L2/16—Methods or apparatus for disinfecting or sterilising materials or objects other than foodstuffs or contact lenses; Accessories therefor using chemical substances
- A61L2/23—Solid substances, e.g. granules, powders, blocks, tablets
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
- A61K47/34—Macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyesters, polyamino acids, polysiloxanes, polyphosphazines, copolymers of polyalkylene glycol or poloxamers
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Epidemiology (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pulmonology (AREA)
- Pain & Pain Management (AREA)
- Rheumatology (AREA)
- Immunology (AREA)
- Otolaryngology (AREA)
- Medicinal Preparation (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Steroid Compounds (AREA)
Abstract
SE REFIERE A UNA FORMULACION FARMACEUTICA EN AEROSOL QUE CONTIENE: A) UNA CANTIDAD TERAPEUTICAMENTE EFECTIVA DE ESTER S-FLUOROMETILICO DE 6ALFA,9ALFA-DIFLUORO-17ALFA[(2-FURANILCARBONIL)OXI]-11BETA-HIDROXI-16ALFA-METIL-3-OXO-ANDROSTA,1,4-DIENO-17BETA-CARBOTIOICO; B) UN PROPULSOR SELECCIONADO DEL GRUPO QUE CONSISTE EN 1,1,2,- TETRAFLUOROETANO ò 1,1,1,2,3,3,3-HEPTAFLUORO-n-PROPANO O UNA MEZCLA DE ESTOS; C) UN POLIMERO BIOCOMPATIBLE EN UN RANGO DE 0.05%-0.2% CON RELACION AL PROPULSOR QUE COMPRENDE UNO MAS COMPUESTOS DE FOMULA (II) DONDE n y m ES UN NUMERO ENTERO DE AL MENOS 1 Y EL VALOR PROMEDIO INDEPENDIENTE DE n y m EN EL POLIMERO BIOCOMPATIBLE ESTA ENTRE 6 y 25. DICHA FORMULACION COMPRENDE ADEMAS UN AGENTE ACTIVO ADICIONAL SELECCIONADO DE SALMETEROL, (R)-SALMETEROL, SALBUTAMOL, TERBUTALINA, ENTRE OTROS. SE REFIERE TAMBIEN A UNA FORMULACION FARMACEUTICA Y UN PROCEDIMIENTO DE PREPARACION. LAS FORMULACIONES DESCRITAS SON UTILES EN EL TRATAMIENTO DE ASMA BROQUIAL, ENFERMEDAD OBSTRUCTIVA PULMONAR CRONICA, Y RELACIONADASREFERS TO A PHARMACEUTICAL FORMULATION IN AEROSOL CONTAINING: A) A THERAPEUTICALLY EFFECTIVE AMOUNT OF 6ALPHA, 9ALPHA-DIFLUORO-17ALPHA [(2-FURANYLCARBONYL) -OXYPHAOXYL-3-HYDROXYL-3-HYDROXYL-3-HYDROXYL-ESTER -ANDROSTE, 1,4-DIENO-17BETA-CARBTIOICO; B) A PROPELLER SELECTED FROM THE GROUP CONSISTING OF 1,1,2, - TETRAFLUOROETHANE ò 1,1,1,2,3,3,3-HEPTAFLUORO-n-PROPANE OR A MIXTURE OF THESE; C) A BIOCOMPATIBLE POLYMER IN A RANGE OF 0.05% -0.2% RELATED TO THE PROPELLER THAT INCLUDES ONE MORE COMPOUNDS OF FORMULA (II) WHERE n and m IS AN INTEGRAL NUMBER OF AT LEAST 1 AND THE INDEPENDENT AVERAGE VALUE OF n and m IN THE BIOTACOMPATIOUS POLYMER IS BETWEEN 6 and 25. SUCH FORMULATION ALSO INCLUDES A SELECTED ADDITIONAL ACTIVE AGENT OF SALMETEROL, (R) -SALMETEROL, SALBUTAMOL, TERBUTALINE, AMONG OTHERS. IT ALSO REFERS TO A PHARMACEUTICAL FORMULATION AND A PREPARATION PROCEDURE. THE DESCRIBED FORMULATIONS ARE USEFUL IN THE TREATMENT OF BROCHIAL ASTHMA, CHRONIC OBSTRUCTIVE PULMONARY DISEASE, AND RELATED
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US78463406P | 2006-03-22 | 2006-03-22 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| PE20080124A1 true PE20080124A1 (en) | 2008-04-21 |
Family
ID=38523271
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| PE2007000310A PE20080124A1 (en) | 2006-03-22 | 2007-03-21 | AEROSOL FORMULATIONS CONTAINING S-FLUOROMETHYL ESTER OF 6ALPHA, 9ALPHA-DIFLUORO-17ALPHA [(2-FURANYLCARBONYL) OXY] -11BETA-HYDROXY-16ALPHA-METHYL-3-OXO-ANDROSTE, 1,4-DIENO-CARBONYL |
Country Status (18)
| Country | Link |
|---|---|
| EP (1) | EP2012797A2 (en) |
| JP (1) | JP2009530419A (en) |
| KR (1) | KR20080110854A (en) |
| CN (1) | CN101415428A (en) |
| AR (1) | AR060039A1 (en) |
| AU (1) | AU2007226899A1 (en) |
| BR (1) | BRPI0708798A2 (en) |
| CA (1) | CA2646236A1 (en) |
| CR (1) | CR10261A (en) |
| EA (1) | EA200801854A1 (en) |
| IL (1) | IL193723A0 (en) |
| MA (1) | MA30328B1 (en) |
| MX (1) | MX2008011967A (en) |
| NO (1) | NO20083760L (en) |
| PE (1) | PE20080124A1 (en) |
| TW (1) | TW200803870A (en) |
| WO (1) | WO2007109698A2 (en) |
| ZA (1) | ZA200807682B (en) |
Families Citing this family (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| ES2994042T3 (en) | 2009-02-26 | 2025-01-16 | Glaxo Group Ltd | Pharmaceutical formulations comprising 4-{(1 r)-2-[(6-{2-[(2,6-dichlorobenzyl)oxy]ethoxy}hexyl)amino]-1-hydroxyethyl}-2-(hydroxymethyl)phenol |
| GB0921075D0 (en) | 2009-12-01 | 2010-01-13 | Glaxo Group Ltd | Novel combination of the therapeutic agents |
Family Cites Families (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA2156408C (en) * | 1993-03-17 | 2005-02-15 | Daniel C. Duan | Aerosol formulation containing a polyester dispersing aid |
| US6750210B2 (en) * | 2000-08-05 | 2004-06-15 | Smithkline Beecham Corporation | Formulation containing novel anti-inflammatory androstane derivative |
| CO5310534A1 (en) * | 2000-08-05 | 2003-08-29 | Glaxo Group Ltd | NEW ANDROSTAN ANTI-INFLAMMATORY DERIVATIVES |
-
2007
- 2007-03-21 CA CA002646236A patent/CA2646236A1/en not_active Abandoned
- 2007-03-21 TW TW096109797A patent/TW200803870A/en unknown
- 2007-03-21 PE PE2007000310A patent/PE20080124A1/en not_active Application Discontinuation
- 2007-03-21 KR KR1020087025825A patent/KR20080110854A/en not_active Withdrawn
- 2007-03-21 CN CNA2007800098351A patent/CN101415428A/en active Pending
- 2007-03-21 EP EP07758963A patent/EP2012797A2/en not_active Withdrawn
- 2007-03-21 WO PCT/US2007/064462 patent/WO2007109698A2/en not_active Ceased
- 2007-03-21 MX MX2008011967A patent/MX2008011967A/en not_active Application Discontinuation
- 2007-03-21 AU AU2007226899A patent/AU2007226899A1/en not_active Abandoned
- 2007-03-21 JP JP2009501708A patent/JP2009530419A/en active Pending
- 2007-03-21 AR ARP070101155A patent/AR060039A1/en not_active Application Discontinuation
- 2007-03-21 BR BRPI0708798-5A patent/BRPI0708798A2/en not_active IP Right Cessation
- 2007-03-21 EA EA200801854A patent/EA200801854A1/en unknown
-
2008
- 2008-08-27 IL IL193723A patent/IL193723A0/en unknown
- 2008-08-28 CR CR10261A patent/CR10261A/en not_active Application Discontinuation
- 2008-09-01 NO NO20083760A patent/NO20083760L/en not_active Application Discontinuation
- 2008-09-05 ZA ZA200807682A patent/ZA200807682B/en unknown
- 2008-10-07 MA MA31274A patent/MA30328B1/en unknown
Also Published As
| Publication number | Publication date |
|---|---|
| MA30328B1 (en) | 2009-04-01 |
| NO20083760L (en) | 2008-12-17 |
| WO2007109698A2 (en) | 2007-09-27 |
| AU2007226899A1 (en) | 2007-09-27 |
| CR10261A (en) | 2008-11-26 |
| KR20080110854A (en) | 2008-12-19 |
| BRPI0708798A2 (en) | 2011-06-14 |
| CN101415428A (en) | 2009-04-22 |
| WO2007109698A3 (en) | 2008-12-18 |
| JP2009530419A (en) | 2009-08-27 |
| EA200801854A1 (en) | 2009-04-28 |
| MX2008011967A (en) | 2009-01-14 |
| AR060039A1 (en) | 2008-05-21 |
| CA2646236A1 (en) | 2007-09-27 |
| ZA200807682B (en) | 2009-11-25 |
| IL193723A0 (en) | 2009-08-03 |
| TW200803870A (en) | 2008-01-16 |
| EP2012797A2 (en) | 2009-01-14 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US20210138071A1 (en) | Silk-based products and methods of use | |
| JP2022003090A (en) | Bismuth-thiols as antiseptics for agricultural, industrial and other uses | |
| WO2021102411A8 (en) | Ionizable lipids and nanoparticle compositions thereof | |
| US9050293B2 (en) | Small molecule solubilization system | |
| ECSP088239A (en) | COMPOSITION OF SUSTAINED DRUG RELEASE | |
| MX2012006720A (en) | Pharmaceutical composition for treatment of dry eye syndrome. | |
| EA200802444A1 (en) | STABILIZED PHARMACEUTICAL COMPOSITIONS CONTAINING PHESTERODINE | |
| AU6947801A (en) | Hyaluronic acid oligosaccharide fractions and drugs containing the same | |
| ES2534843T3 (en) | Antimicrobial and anti-acne formulations | |
| KR20060118443A (en) | Antimicrobial Compositions and Methods | |
| DE602006004451D1 (en) | MUCOADHESIVE XYLOGLUCAN-CONTAINING FORMULATION FOR MEDICAL PRODUCTS AND PHARMACEUTICAL PHARMACEUTICAL FORMS | |
| WO2009095226A3 (en) | NUCLEIC ACIDS COMPRISING FORMULA (NuGlXmGnNv)a AND DERIVATIVES THEREOF AS AN IMMUNOSTIMULATING AGENTS /ADJUVANTS | |
| WO2005004917A3 (en) | Pharmaceutical composition for solubility enhancement of hydrophobic drugs | |
| ECSP088653A (en) | PHARMACEUTICAL FORMULATION FOR AEROSOLS WITH TWO OR MORE ACTIVE PRINCIPLES AND AT LEAST A TENSOACTIVE SUBSTANCE | |
| WO2007084247A3 (en) | Stable therapeutic formulations | |
| NZ602538A (en) | Thermogelling anaesthetic compositions | |
| PE20091949A1 (en) | SOLID PHARMACEUTICAL FORMULATION WITH DELAYED RELEASE | |
| MXPA05001061A (en) | PHARMACEUTICAL, WATERY COMPOSITIONS OF 2,6-DIISOPROPYLPENOL. | |
| ECSP088240A (en) | COMPOSITION OF TRAZODONE FOR ADMINISTRATION ONCE A DAY | |
| JP2007530573A5 (en) | ||
| DE102014009164A1 (en) | Silicone oil containing nasal formulations | |
| KR20090122438A (en) | Medical Solvation Systems and Sealants | |
| PE20080124A1 (en) | AEROSOL FORMULATIONS CONTAINING S-FLUOROMETHYL ESTER OF 6ALPHA, 9ALPHA-DIFLUORO-17ALPHA [(2-FURANYLCARBONYL) OXY] -11BETA-HYDROXY-16ALPHA-METHYL-3-OXO-ANDROSTE, 1,4-DIENO-CARBONYL | |
| ES2860098T3 (en) | Composition for nasal application | |
| PE17897A1 (en) | TRANSDERMIC FORMULATION IN PATCH OF 3- (4-BUTILTIO) -1,2,5-TIADIAZOL-3-IL) -1-AZABICICLO (2,2,2) OCTANO |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FD | Application declared void or lapsed |